Valuation: Alvotech

Market Cap 138.48Cr 119.55Cr 112.16Cr 102.16Cr 192.08Cr 13TCr 194.75Cr 1.31TCr 515.22Cr 6.63TCr 519.92Cr 508.66Cr 22TCr P/E 2026 *
14.6x
P/E 2027 * 8.46x
Enterprise Value 246.82Cr 213.08Cr 199.91Cr 182.08Cr 342.36Cr 24TCr 347.11Cr 2.34TCr 918.31Cr 12TCr 926.68Cr 906.61Cr 39TCr EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.13x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.30%
1 week+3.09%
Current month+3.78%
1 month+13.78%
3 months+21.90%
6 months-3.52%
Current year-17.31%
1 week 36.1
Extreme 36.1
39.5
1 month 30.6
Extreme 30.6
40.65
Current year 27.5
Extreme 27.5
50.26
1 year 27.5
Extreme 27.5
86.22
3 years 27.5
Extreme 27.5
157
5 years 27.5
Extreme 27.5
157
10 years 27.5
Extreme 27.5
157
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+3.09% - - 138.48Cr
-0.11%-1.67%+1.80%+19.90% 4.88TCr
+0.58%+3.42%+483.24%+617.72% 4.54TCr
+1.58%+2.38%+15.29%+90.69% 4.12TCr
+0.66%-0.26%+26.31%+13.66% 3.97TCr
-2.74%-2.74%+17.30%+56.10% 3.26TCr
+1.84%-1.68% - - 1.62TCr
-0.60%-1.85%+28.39%+138.03% 1.67TCr
-0.49%-0.34%+3.45%+29.14% 1.41TCr
-0.67%+0.48%+80.51%+42.46% 1.37TCr
Average -0.12%-0.78%+82.03%+125.96% 2.98TCr
Weighted average by Cap. +0.10%-0.84%+102.71%+152.40%

Financials

2026 *2027 *
Net sales 66Cr 57Cr 53Cr 48Cr 91Cr 6.27TCr 92Cr 622.67Cr 244Cr 3.14TCr 246.23Cr 240.9Cr 10TCr 78Cr 67Cr 63Cr 57Cr 108.05Cr 7.45TCr 109.55Cr 739.61Cr 289.83Cr 3.73TCr 292.47Cr 286.14Cr 12TCr
Net income 9.18Cr 7.92Cr 7.43Cr 6.77Cr 13Cr 877.69Cr 13Cr 87Cr 34Cr 439.72Cr 34Cr 34Cr 1.46TCr 15Cr 13Cr 12Cr 11Cr 21Cr 1.45TCr 21Cr 143.72Cr 56Cr 725.1Cr 57Cr 56Cr 2.41TCr
Net Debt 108.34Cr 94Cr 88Cr 80Cr 150.28Cr 10TCr 152.36Cr 1.03TCr 403.09Cr 5.19TCr 406.76Cr 397.95Cr 17TCr 105.6Cr 91Cr 86Cr 78Cr 146.48Cr 10TCr 148.51Cr 1TCr 392.9Cr 5.06TCr 396.48Cr 387.89Cr 17TCr
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
18/26/18 SEK 38.40 -0.26% 7,760
17/26/17 SEK 38.50 -0.13% 13,488
14/26/14 SEK 38.55 +1.45% 33,130
13/26/13 SEK 38.00 +4.11% 15,258
12/26/12 SEK 36.50 -2.01% 6,43,066
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.880USD
Average target price
5.750USD
Spread / Average Target
+48.20%

Quarterly revenue - Rate of surprise